🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanced cancers

    Janssen-Cilag International N.V.

    Previously treated lymphoma (blood cancer) or solid tumors and NHL

    phase 1 other active

    1 trial

  2. A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

    GlaxoSmithKline

    Autosomal Dominant Polycystic Kidney Disease

    phase 1 other active

    1 trial

  3. A study to learn about how a new nurandociguat tablet is absorbed and processed in the body compared to an old tablet and how food affects the way the new tablet is absorbed and processed in the body

    Bayer AG

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  4. A study to learn about how itraconazole affects the level of emodepside in the blood when emodepside is given as a new type of tablet to healthy participants

    Bayer AG

    Soil-transmitted helminth infection, Onchocerciasis (river blindness)

    phase 1 other active

    1 trial

  5. A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  6. A study to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis and coagulopathy

    Bayer AG

    Coagulopathy, Sepsis

    phase 1 other active

    1 trial

  7. A study to learn about the amount of asundexian in the blood when healthy participants take different types of asundexian tablets

    Bayer AG

    Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack

    phase 1 other active

    1 trial

  8. A study to learn about the safety of BAY 3283142 in people with mild to moderate high blood pressure

    Bayer AG

    Chronic kidney disease

    phase 1 other active

    1 trial

  9. A study to learn about the study medicine called PF-08046032 in people with advanced cancers.

    Pfizer Australia Pty Ltd

    Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma)

    phase 1 other active

    1 trial

  10. A study to learn about the taste of Vericiguat given in liquid form in healthy male participants aged 18 to 45 years

    Bayer AG

    Heart failure in children

    phase 1 other active

    1 trial

  11. A study to learn how asundexian affects the amount of metformin in the blood when healthy participants take them together

    Bayer AG

    Prevention of ischemic stroke in patients after an acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack in combination with antiplatelet therapy

    phase 1 other active

    1 trial

  12. A study to learn how different amounts of the study medicine called PF-07941944 are tolerated in the body of healthy adults.

    Pfizer Australia Pty Ltd

    RSV (Respiratory Syncytial Virus)

    phase 1 other active

    1 trial

  13. A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  14. A study to learn how vamorolone affects the body, how safe it is and how it moves into, through and out of the body in healthy male participants

    Lacuna Pharma Pty Ltd

    Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy

    phase 1 other active

    1 trial

  15. A study to learn how zilucoplan moves throughout the body over time when given in 2 different ways in healthy adults

    Lacuna Pharma Pty Ltd

    Healthy Volunteers

    phase 1 other active

    1 trial

  16. A study to learn if UCB3101 is safe and how it moves through the body of healthy participants

    Lacuna Pharma Pty Ltd

    Healthy Participants

    phase 1 other active

    1 trial

  17. A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults

    Lacuna Pharma Pty Ltd

    CCI

    phase 1 other active

    1 trial

  18. A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.

    Bayer AG

    Chronic kidney disease

    phase 1 other active

    1 trial

  19. A study to learn more about how safe nurandociguat is and how it affects the way the body processes rosuvastatin and dabigatran in healthy adults

    Bayer AG

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  20. A study to learn more about the safety and effects of a new blood-thinning medicine, given alone and together with another blood-thinner, in healthy adults

    Bayer AG

    atrial fibrillation, transient ischemic attack (TIA), ischemic stroke

    phase 1 other active

    1 trial

  21. A study to test a medicine (fitusiran) for preventing bleeds in people with severe hemophilia who previously received preventive treatment with emicizumab

    Sanofi-aventis Healthcare Pty Ltd

    Hemophilia A

    phase 1 other active

    1 trial

  22. A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation.

    Boehringer Ingelheim

    solid tumour harbouring G12C mutation

    phase 1 other active

    1 trial

  23. A study to test different doses of obrixtamig (BI 764532) in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.

    Boehringer Ingelheim

    Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

    phase 1 other active

    1 trial

  24. A study to test how BI 456906 is taken up in the blood of people with and without kidney problems

    Boehringer Ingelheim

    Renal impairment (mild, moderate and severe), Healthy

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources